Search

Displaying results 2291 - 2300 of 10000 in total
  1. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    small cell lung cancer (ES-SCLC). … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in

  2. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … the prevention of postmenopausal osteoporosis in women.

  3. Drug

    Methyldopa

    go.drugbank.com/drugs/DB00968
    ApprovedInvestigational

    [A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. … [A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency.

    International brands: Nu-MedopaProducts: Nu-medopa Tab 250mg, Nu-medopa Tab 500mg
  4. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions. … (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages.

  5. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.

    Synonyms: 1-Methyl-4-amino-N-phenyl-N-(2-thenyl)piperidine, 1-Methyl-4-N-2-thenylanilinopiperidine
  6. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.

  7. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014. … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.

  8. Drug

    Anethole trithione

    go.drugbank.com/drugs/DB13853
    Approved

    hepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614]. … Anethole trithione (ATT) appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to

  9. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine [A32042]. … In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046].

    Synonyms: D6 tetrabenazine, D6-tetrabenazine
  10. Drug

    Tyropanoic acid

    go.drugbank.com/drugs/DB09340
    Approved

    The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image [L1608]. … Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac.

    Categories: Compounds used in a research, industrial, or household setting